(Press-News.org) Oncotarget recently published "Polymerized human hemoglobin increases the effectiveness of cisplatin-based chemotherapy in non-small cell lung cancer" which reported that unfortunately, a significant portion of NSCLC patients relapse due to cisplatin chemoresistance.
Administration of hemoglobin-based oxygen carriers is a promising strategy to alleviate hypoxia in the tumor, which may make cisplatin more effective.
The R-state PolyHb administered in this study is unable to deliver O2 unless under severe hypoxia which significantly limits its oxygenation potential.
In vitro sensitivity studies indicate that the administration of PolyHb increases the effectiveness of cisplatin under hypoxic conditions.
Additional animal studies revealed that co-administration of PolyHb with cisplatin attenuated tumor growth without alleviating hypoxia.
Additional animal studies revealed that co-administration of PolyHb with cisplatin attenuated tumor growth without alleviating hypoxia
Dr. Pedro Cabrales from The Department of Bioengineering at The University of California San Diego said, "Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer death and constitutes ~80 to 85% of all types of lung cancers."
Furthermore, the expression of HIF-1α is associated with the reduction of ROS in cancer cells, which promotes cancer cell survival.
In an attempt to reverse the tumor's hypoxic microenvironment, several studies have supplemented cisplatin treatment with hemoglobin-based oxygen carriers.
The above studies have been capable of effectively increasing the sensitivity of cancerous cells to cisplatin, both in vitro and in vivo, via supplementation of HBOCs, and they attribute this gained efficacy to increased O2 delivery.
However, the concentrations of HBOC used in previous studies were insufficient to provide a significant increase in tumor O2 delivery.
Hence, this study explores both mechanisms, i. e., the increase in oxygenation of the tumor and the catalyzed formation of ROS by the HBOC, in in vitro and in vivo studies using low molecular weight polymerized human Hb in the relaxed quaternary state.
The Cabrales Research Team concluded in their Oncotarget Research paper that this study serves as preliminary evidence of PolyHb's ability to increase the sensitivity to cisplatin in NSCLC.
The evidence presented in this study suggests that decreased hypoxia due to facilitated O2 delivery combined with endogenous O2 delivery in the animal might have a small effect on cisplatin sensitization.
Future studies should aim at utilizing in vivo approaches for both ROS detection and intravascular oxygenation in the implanted tumors, as an approach for determining the effects of PolyHb in these two essential processes.
Additionally, these studies should consider incorporating superoxide dismutase and catalase to evaluate the exact modes of ROS generation that influence the chemosensitization mechanism as a function of environmental O2 tension.
Future studies should also explore how the administration of PolyHb solutions modulates prolyl hydroxylase, gene expression, and protein expression after extended doses.
INFORMATION:
Sign up for free Altmetric alerts about this article
DOI - https://doi.org/10.18632/oncotarget.27776
Full text - https://www.oncotarget.com/article/27776/text/
Correspondence to - Pedro Cabrales - pcabrales@ucsd.edu
Keywords -
chemotherapy,
cisplatin,
polymerized hemoglobin,
non-small cell lung cancer,
hypoxia
About Oncotarget
Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105
BOSTON -- While PCR testing has been used widely for COVID-19 diagnosis, it only provides information on who is currently infected. Antibody testing can tell who has been previously exposed to SARS-CoV-2, the virus that causes COVID-19, a metric that is essential for tracking spread across a population. It may also, as a study recently published in the journal Nature Communications shows, hold the key to understanding the immune response to the virus.
Led by Galit Alter, PhD, Core Member of the Ragon Institute of MGH, MIT and Harvard, this study found that while antibodies against SARS-CoV-2 may be a good way to measure exposure to the virus, their presence alone wasn't enough to determine if a person had long-lasting protection. Instead, antibody effector functions associated ...
OAK BROOK, Ill. - Radiomics--the extraction of very detailed quantitative features from medical images--provides a refined understanding of how cocaine use and other risk factors affect the course of coronary artery disease, according to a study published in Radiology. Researchers said the study shows the power of radiomics to improve understanding of not just cardiovascular disease, but cancer and other conditions as well.
Coronary artery disease typically develops over time as plaque builds up inside the arteries. This process, known as atherosclerosis, ...
OAK BROOK, Ill. - Researchers using MRI have found significant abnormalities in the eyes of some people with severe COVID-19, according to a study published in the journal Radiology. The study results support the need for eye screening in these patients to provide appropriate treatment and management of potentially severe ophthalmological manifestations of COVID-19.
The COVID-19 pandemic has affected more than 100 million people since it began early in 2020. While the virus primarily attacks the lungs, it has been linked with eye abnormalities ...
Launched in 1988, the Global Polio Eradication Initiative (GPEI) stands out as one of the largest, internationally coordinated global public health major projects conducted to date, with cumulative spending of over $16.5 billion for 1988-2018, according to the World Health Organization (WHO). More than 30 years later, stubborn outbreaks of wild poliovirus still occur in Afghanistan and Pakistan, where cases have been increasing since 2018. The global eradication of polio continues to be an elusive goal.
A special issue of the journal Risk Analysis, titled "Global Poliovirus Risk Management and Modeling," looks at the current status of polio eradication ...
Earth is home to millions of known species of plants and animals, but by no means are they distributed evenly. For instance, rainforests cover less than 2 percent of Earth's total surface, yet they are home to 50 percent of Earth's species. Oceans account for 71 percent of Earth's total surface but contain only 15 percent of Earth's species. What drives this uneven distribution of species on Earth is a major question for scientists.
In a paper published February 16 in the Journal of Biogeography an international team of researchers led by Jacob S. Suissa, Ph.D. Candidate in the Department of Organismic and Evolutionary Biology, ...
Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium held virtually February 11-13. Notably, MSK medical oncologist Robert Motzer, MD, presented encouraging data from a phase III randomized study that assessed two new treatment combinations as first-line treatments that may prolong survival in people with advanced kidney cancer. Dr. Motzer's findings were also published on February 13 in the New England Journal of Medicine.
In this large, international trial involving 200 sites across 20 countries, Dr. Motzer and a team of investigators ...
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) - called NPM1 - that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation.
In research published Feb. 16, in Nature Communications, a team led by Princess Margaret Cancer Centre Senior Scientists, Drs. Benjamin Haibe-Kains, Aaron Schimmer and Mark Minden, have discovered that within the NPM1 mutation of AML there exists two unique subtypes, one of which can be effectively treated with drugs already in use.
It is the first study to classify within the common NPM1 mutant form of AML two subtypes, one being "primitive" and the other ...
Most people infected with SARS-CoV-2 are able to recover from the disease at home - even if they might experience very stressful disease progressions. Some have no symptoms at all. But about ten percent of those affected become so severely ill that they have to be treated in a hospital. The assumption that a weak immune system is behind a severe progression is short-sighted. Especially with critical progressions, the immune system works under intense pressure, but does not manage to control the virus.
A Berlin research group has now observed how SARS-CoV-2 uses an immune system defense mechanism to increasingly hijack ...
Computing - Modeling COVID dynamics
To better understand the spread of SARS-CoV-2, the virus that causes COVID-19, Oak Ridge National Laboratory researchers have harnessed the power of supercomputers to accurately model the spike protein that binds the novel coronavirus to a human cell receptor.
These simulations also shed light on the ligand molecules that can inhibit such binding, pointing the way to potential drug therapies.
An ultrafast quantum chemical modeling method provides information about the critical electronic interactions between protein and ligand chemicals, going beyond the classical interaction models that are normally employed in computational drug discovery.
The findings will enable accurate predictions of the performance of currently available inhibitors ...
The University of Kent has led a study highlighting the urgent need for the UK's Government and renewable energy industries to give vital attention to decommissioning offshore wind turbines approaching their end of live expectancy by 2025. The research reveals that the UK must decommission approximately 300 and 1600 early-model offshore wind turbines by 2025 and 2030, respectively.
Urgent focus is needed now to proactively use the remaining years until turbines installed in the 1990s and early 2000s are no longer safely functional in 2025, to prevent safety lapses, potentially huge costs and the irretrievable loss of the skillset required for safe decommission.
The research shows that these original turbines have an approximate lifetime of 20 to 25 years, but this expectation ...
